eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.
Epistemonikos ID: 7f1967a381488b3078638e3e9608845f82bd974e
First added on: Sep 18, 2025